Immunologic Biomarker Findings for mFOLFOX6 and Pembrolizumab in CRC

In an interview with Targeted Oncology, Jeff Stein, PhD, discussed the challenges and prospects of CD73-targeting agents.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Results from a phase 1/2a trial showed that plixorafenib had potential regarding safety and efficacy in BRAF-mutated solid tumors, especially in primary central nervous system tumors.

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

In an interview with Targeted Oncology, City of Hope cancer center’s Marwan Fakih, MD, further discussed the findings from this phase 3 trial and future directions for evaluating this combination.

Julia Rotow, MD, discussed emerging data on upfront therapies for patients with lung cancer harboring EGFR mutations in a presentation at the 18th Annual New York Lung Cancers Symposium.